TY - JOUR
T1 - Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response
AU - Morris, Gerwyn
AU - Gamage, Elizabeth
AU - Travica, Nikolaj
AU - Berk, Michael
AU - Jacka, Felice N.
AU - O'Neil, Adrienne
AU - Puri, Basant K.
AU - Carvalho, Andre F.
AU - Bortolasci, Chiara C.
AU - Walder, Ken
AU - Marx, Wolfgang
N1 - Funding Information:
Michael Berk is supported by a NHMRC Senior Principal Research Fellowship ( 1059660 and 1156072 ). Michael Berk has received Grant/Research Support from the NIH , Cooperative Research Centre , Simons Autism Foundation , Cancer Council of Victoria , Stanley Medical Research Foundation , Medical Benefits Fund, National Health and Medical Research Council , Medical Research Futures Fund , Beyond Blue , Rotary Health , A2 milk company , Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation, has been a speaker for Abbot, Astra Zeneca, Janssen and Janssen, Lundbeck and Merck and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier – all unrelated to this work. Wolfgang Marx is currently funded by an Alfred Deakin Postdoctoral Research Fellowship and a Multiple Sclerosis Research Australia early-career fellowship. Wolfgang has previously received funding from the NHMRC , Clifford Craig Foundation , Cancer Council Queensland and university grants/fellowships from La Trobe University , Deakin University , University of Queensland , and Bond University , received industry funding and has attended events funded by Cobram Estate Pty. Ltd, received travel funding from Nutrition Society of Australia, received consultancy funding from Nutrition Research Australia, and has received speakers honoraria from The Cancer Council Queensland and the Princess Alexandra Research Foundation . Adrienne O'Neil is supported by a Future Leader Fellowship (# 101160 ) from the Heart Foundation Australia and Wilson Foundation . She has received research funding from the National Health & Medical Research Council , Australian Research Council , University of Melbourne , Deakin University , Sanofi , Meat and Livestock Australia and Woolworths Limited and Honoraria from Novartis . The Food & Mood Centre has received funding from the Fernwood Foundation , the A2 Milk Company and Be Fit Foods. Felice Jacka has received Grant/Research support from the Brain and Behaviour Research Institute, the National Health and Medical Research Council ( NHMRC ), Australian Rotary Health , the Geelong Medical Research Foundation , the Ian Potter Foundation , Eli Lilly , Meat and Livestock Australia , Woolworths Limited, Fernwood Foundation , Wilson Foundation , The A2 Milk Company, Be Fit Foods, and The University of Melbourne and has received speakers honoraria from Sanofi-Synthelabo, Janssen Cilag , Servier , Pfizer , Health Ed, Network Nutrition, Angelini Farmaceutica, Eli Lilly and Metagenics. Felice Jacka has written two books for commercial publication and has a personal belief that good diet quality is important for mental and brain health.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/8/20
Y1 - 2021/8/20
N2 - The pathophysiology of psychiatric and neurodegenerative disorders is complex and multifactorial. Polyphenols possess a range of potentially beneficial mechanisms of action that relate to the implicated pathways in psychiatric and neurodegenerative disorders. The aim of this review is to highlight the emerging clinical trial and preclinical efficacy data regarding the role of polyphenols in mental and brain health, elucidate novel mechanisms of action including the gut microbiome and gene expression, and discuss the factors that may be responsible for the mixed clinical results; namely, the role of interindividual differences in treatment response and the potentially pro-oxidant effects of some polyphenols. Further clarification as part of larger, well conducted randomized controlled trials that incorporate precision medicine methods are required to inform clinical efficacy and optimal dosing regimens.
AB - The pathophysiology of psychiatric and neurodegenerative disorders is complex and multifactorial. Polyphenols possess a range of potentially beneficial mechanisms of action that relate to the implicated pathways in psychiatric and neurodegenerative disorders. The aim of this review is to highlight the emerging clinical trial and preclinical efficacy data regarding the role of polyphenols in mental and brain health, elucidate novel mechanisms of action including the gut microbiome and gene expression, and discuss the factors that may be responsible for the mixed clinical results; namely, the role of interindividual differences in treatment response and the potentially pro-oxidant effects of some polyphenols. Further clarification as part of larger, well conducted randomized controlled trials that incorporate precision medicine methods are required to inform clinical efficacy and optimal dosing regimens.
UR - http://www.scopus.com/inward/record.url?scp=85107708011&partnerID=8YFLogxK
U2 - 10.1016/j.freeradbiomed.2021.05.036
DO - 10.1016/j.freeradbiomed.2021.05.036
M3 - Review article
C2 - 34062263
AN - SCOPUS:85107708011
SN - 0891-5849
VL - 172
SP - 101
EP - 122
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
ER -